title: Janus reveals another face: the biologic rationale for targeting Janus kinase 2 in lymphoma.
authors.affiliation: Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Ann
authors.initials: A
authors.lastname: Mullally
authors.forename: Benjamin L
authors.initials: BL
authors.lastname: Ebert
mesh_terms: D001952:Bridged-Ring Compounds / Q000008:administration & dosage* / Q000009:adverse effects*; D005260:Female; D006801:Humans; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors*; D008223:Lymphoma / Q000188:drug therapy* / Q000201:enzymology*; D008297:Male; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects*
chemical_list: C561234:11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene; D001952:Bridged-Ring Compounds; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D053614:Janus Kinase 2